These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 16344381)

  • 1. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials.
    Eikelboom JW; Quinlan DJ; Mehta SR; Turpie AG; Menown IB; Yusuf S
    Circulation; 2005 Dec; 112(25):3855-67. PubMed ID: 16344381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials.
    De Luca G; Marino P
    Am Heart J; 2007 Dec; 154(6):1085.e1-6. PubMed ID: 18035079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
    Sabatine MS; Morrow DA; Montalescot G; Dellborg M; Leiva-Pons JL; Keltai M; Murphy SA; McCabe CH; Gibson CM; Cannon CP; Antman EM; Braunwald E;
    Circulation; 2005 Dec; 112(25):3846-54. PubMed ID: 16291601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials.
    Dumaine R; Borentain M; Bertel O; Bode C; Gallo R; White HD; Collet JP; Steinhubl SR; Montalescot G
    Arch Intern Med; 2007 Dec; 167(22):2423-30. PubMed ID: 18071163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
    Sabatine MS; Morrow DA; Dalby A; Pfisterer M; Duris T; Lopez-Sendon J; Murphy SA; Gao R; Antman EM; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(23):2256-63. PubMed ID: 17560290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-molecular-weight heparins in conjunction with thrombolysis for ST-elevation acute myocardial infarction. A critical review of the literature.
    Rubboli A; Ottani F; Capecchi A; Brancaleoni R; Galvani M; Swahn E
    Cardiology; 2007; 107(2):132-9. PubMed ID: 16864962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial.
    Morrow DA; Antman EM; Murphy SA; Qin J; Ruda M; Guneri S; Jacob AJ; Budaj A; Braunwald E;
    Am Heart J; 2007 Dec; 154(6):1078-84, 1084.e1. PubMed ID: 18035078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of unfractionated heparin and low molecular weight heparin in pulmonary thromboembolism: meta-analysis].
    Zhai ZG; Wang C; Liu YM; Qin ZQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Jun; 26(3):221-6. PubMed ID: 15266820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving role of low-molecular-weight heparins in ST-elevation myocardial infarction.
    Kalus JS; Moser LR
    Ann Pharmacother; 2005 Mar; 39(3):481-91. PubMed ID: 15701782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-molecular-weight heparin versus unfractionated heparin in acute ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with drug-eluting stents.
    Li YJ; Rha SW; Chen KY; Poddar KL; Jin Z; Minami Y; Wang L; Dang Q; Li GP; Ramasamy S; Park JY; Choi CU; Kim JW; Kim EJ; Park CG; Seo HS; Oh DJ; Jeong MH; Ahn YK; Hong TJ; Park JS; Kim YJ; Hur SH; Seong IW; Chae JK; Cho MC; Bae JH; Choi DH; Jang YS; Chae IH; Kim HS; Kim CJ; Yoon JH; Ahn TH; Tahk SJ; Chung WS; Seung KB; Park SJ;
    Am Heart J; 2010 Apr; 159(4):684-690.e1. PubMed ID: 20362730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
    Califf RM; Petersen JL; Hasselblad V; Mahaffey KW; Ferguson JJ
    Am Heart J; 2005 Apr; 149(4 Suppl):S91-9. PubMed ID: 16124953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.
    Eikelboom JW; Anand SS; Malmberg K; Weitz JI; Ginsberg JS; Yusuf S
    Lancet; 2000 Jun; 355(9219):1936-42. PubMed ID: 10859038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials.
    Wein L; Wein S; Haas SJ; Shaw J; Krum H
    Arch Intern Med; 2007 Jul; 167(14):1476-86. PubMed ID: 17646601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
    Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis.
    Murphy SA; Gibson CM; Morrow DA; Van de Werf F; Menown IB; Goodman SG; Mahaffey KW; Cohen M; McCabe CH; Antman EM; Braunwald E
    Eur Heart J; 2007 Sep; 28(17):2077-86. PubMed ID: 17600038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction.
    Zeymer U; Gitt A; Jünger C; Bauer T; Heer T; Koeth O; Wienbergen H; Zahn R; Senges J
    Thromb Haemost; 2008 Jan; 99(1):150-4. PubMed ID: 18217147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of bleeding complications and 3-year survival with low-molecular-weight heparin versus unfractionated heparin for acute myocardial infarction: the FAST-MI registry.
    Puymirat É; Aissaoui N; Silvain J; Bonello L; Cuisset T; Motreff P; Bataille V; Durand E; Cottin Y; Simon T; Danchin N;
    Arch Cardiovasc Dis; 2012; 105(6-7):347-54. PubMed ID: 22800719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis.
    Giraldez RR; Nicolau JC; Corbalan R; Gurfinkel EP; Juarez U; Lopez-Sendon J; Parkhomenko A; Molhoek P; Mohanavelu S; Morrow DA; Antman EM
    Eur Heart J; 2007 Jul; 28(13):1566-73. PubMed ID: 17562672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.